Skip to main content

Table 2 Summary of clinical response.

From: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus

Patient number

Clinical outcome

Time to complete response (weeks)

Follow-up period (months)

Maximun dose received (mg)

Relapse

Dose at relapse

1

CR

10

15

5

Yes

5 mg twice weekly

2

CR

4

12

5

Yes

5 mg three times weekly

3

Withdrawn

-

-

5

-

-

4

CR

3

12

5

Yes

5 mg alternate days

5

CR

36

19

5

-

-

6

CR

4

17

5

No

-

7

CR

11

18

5

No

-

8

CR

2

7

5

Yes

5 mg alternate days

9

PR

-

15

10

-

-

10

CR

7

10

5

Yes

5 mg alternate days

11

CR

4

30

5

Yes

5 mg twice weekly

12

CR

4

25

5

Yes

5 mg alternate days

13

PR

-

8

5

-

-

14

CR

12

17

5

Yes

5 mg three times weekly

15

CR

2

10

5

Yes

5 mg alternate days

  1. CR, complete response; PR, partial response.